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Abstract
Deficiencies in the mismatch repair (MMR) pathway are associated with several types of cancers,
as well as resistance to commonly used chemotherapeutics. Rhodium metalloinsertors have been
found to bind DNA mismatches with high affinity and specificity in vitro, and also exhibit cell-
selective cytotoxicity, targeting MMR-deficient cells over MMR-proficient cells. Ten distinct
metalloinsertors with varying lipophilicities have been synthesized and their mismatch binding
affinities and biological activities determined. Although DNA photocleavage experiments
demonstrate that their binding affinities are quite similar, their cell-selective antiproliferative and
cytotoxic activities vary significantly. Inductively coupled plasma mass spectrometry (ICP-MS)
experiments have uncovered a relationship between the subcellular distribution of these
metalloinsertors and their biological activities. Specifically, we find that all of our metalloinsertors
localize in the nucleus at sufficient concentrations for binding to DNA mismatches. However, the
metalloinsertors with high rhodium localization in the mitochondria show toxicity that is not
selective for MMR-deficient cells, whereas metalloinsertors with less mitochondrial rhodium
show activity that is highly selective for MMR-deficient versus proficient cells. This work
supports the notion that specific targeting of the metalloinsertors to nuclear DNA gives rise to
their cell-selective cytotoxic and antiproliferative activities. The selectivity in cellular targeting
depends upon binding to mismatches in genomic DNA.
INTRODUCTION
The cell has evolved a complex replication mechanism containing multiple checkpoints in
order to minimize the incorporation of errors during replication and correct errors that result
from chemical damage to DNA after replication.1 Left uncorrected, these DNA defects will
lead to mutations in subsequent rounds of replication.2,3, The mismatch repair (MMR)
pathway provides one such checkpoint and increases the fidelity of DNA replication ~1000-
fold.4 Not surprisingly, defects in this pathway have been associated with several types of
cancer. For example, about 18% of solid tumors and 15% of sporadic colorectal cancer cases
have been found to exhibit MMR deficiencies.5,6, Furthermore, many commonly used
chemotherapeutics, such as cisplatin, DNA alkylating agents, and anti-metabolites, have
decreased effectiveness against MMR-deficient cancer cells.7 In fact, repeated
chemotherapeutic treatments with these agents enrich tumors with MMR-deficient cells.8,9,
Undeniably, then, the synthesis and study of small molecules that possess the ability to
specifically target DNA defects may afford progress in the development of new cancer
diagnostics and therapeutics that are specific for MMR-deficient cancers.
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Our laboratory has previously developed a class of compounds, called rhodium
metalloinsertors (Figure 1), that target DNA mismatches in vitro with high specificity and
affinity.10 The first generation compound, [Rh(bpy)2(chrysi)]3+ (chrysi= chrysene-5,6-
quinonediimine), binds 80% of DNA mismatches in all sequence contexts and preferentially
targets thermodynamically destabilized mismatches over matched base pairs by a factor of
over 1000.11 Specifically, it has been shown to bind only at the single mismatch site in a
2725 base-pair plasmid.12 Additional work focused on incorporating nitrogen atoms into the
intercalating ligand in order to increase π-stacking stabilization and led to the development
of our second generation compound, [Rh(bpy)2(phzi)]3+ (phzi = benzo [a] phenazine-5,6-
quinonediimine). This complex exhibits a 50-fold increase in binding affinity compared to
[Rh(bpy)2(chrysi)]3+ without a loss in selectivity, allowing for mismatch detection at
nanomolar Rh concentrations.13 The binding mode of these mismatch-specific complexes
was determined through the 1.1 Å resolution crystal structure of [Rh(bpy)2(chrysi)]3+ bound
to an AC mismatch. The structure revealed the chrysi ligand to insert from the minor groove
with ejection of both mismatched bases.14 NMR studies of [Rh(bpy)2(chrysi)]3+ bound to a
CC mismatch further confirmed this binding mode for the complex at mismatched sites in
solution.15 Additional crystal structures of the Rh complex bound to different mismatches 16
as well as of a Ru complex bound by insertion to a mismatched site17 established the
generality of metalloinsertion. It is noteworthy that these studies represented the first
illustration of the insertion binding mode, proposed originally by L. S. Lerman in the early
1960’s.18
In an effort to characterize the in cellulo effects of these metalloinsertors, several cell assay
experiments have been undertaken on the isogenic cell lines HCT116N and HCT116O. The
HCT116 parent cell line is a human colorectal carcinoma line deficient in the hMLH1 gene.
This gene encodes for part of the mismatch repair (MMR) machinery; consequently this cell
line is MMR deficient. The HCT116N cell line has been transfected with human
chromosome 3 (ch3), which restores MMR proficiency, while the HCT116O cell line has
been transfected with human chromosome 2 (ch2), leaving it MMR deficient.19 These
rhodium metalloinsertors have been found selectively to inhibit DNA synthesis in the
MMR-deficient HCT116O cell line over the MMR-proficient HCT116N cell line,20 as
measured by an ELISA assay for DNA synthesis.21 Significantly, the binding affinities of
the metalloinsertors were found to correlate directly with the selectivity of the rhodium
complexes for the MMR-deficient cell line, lending credence to the idea that these
complexes target DNA mismatches in cellulo as well as in the test tube.22
Recently it was discovered that the rhodium metalloinsertors that display activity at
relatively short incubation times in the ELISA assay also show preferential cytotoxicity
towards the MMR-deficient HCT116O cell line, inducing death via a necrotic pathway.23 As
one generally accepted trigger of necrosis is severe ATP depletion,24,25, this observation
prompted the investigation of subcellular localization. These metalloinsertors may trigger
necrosis through mitochondrial DNA targeting. As lipophilic cations, mitochondrial
accumulation is a possibility;26 real-time monitoring of the cells with confocal microscopy
could not be used to monitor organelle accumulation, however, since the rhodium
complexes are not luminescent. Nonetheless, an understanding of the subcellular
localization of these compounds is crucial for the development of next-generation
metalloinsertors with improved selectivity for MMR-deficient cells.27 Rhodium uptake can
be easily probed by inductively coupled plasma mass spectrometry (ICP-MS), as no
interfering ion exists within the cell. The sensitivity of ICP-MS allows for biologically
relevant concentrations of rhodium to be determined,28 and combined with organelle
isolation procedures, ICP-MS can be used to give estimates on the subcellular localization of
our metalloinsertors.
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Here we correlate the selectivity of a variety of rhodium metalloinsertors that target MMR-
deficient cells with the subcellular localization of the complexes. We find that all complexes
studied are localized at a sufficient concentration in the nucleus for mismatch binding.
Furthermore, we find that, in general, higher levels of mitochondrial rhodium reduce the
cell-selective biological activity of these metalloinsertors. These observations give credence
to the theory that mismatches in genomic DNA are the ultimate target of our
metalloinsertors and that this mismatch targeting is responsible for their unique cell-
selective biological activity.
EXPERIMENTAL
Materials
Commercially available chemicals were used as received. The Rh complex
[Rh(NH3)5Cl]Cl2 was obtained from Strem Chemical, Inc. RhCl3 was purchased from
Pressure Chemical, Inc. All organic reagents and Sephadex ion-exchange resin were
obtained from Sigma-Aldrich unless otherwise noted. Sep-pak C18 solid-phase extraction
cartridges were purchased from Waters Chemical Co. (Milford, MA). Media and
supplements were purchased from Invitrogen (Carlsbad, CA). BrdU, antibodies, buffers,
peroxidase substrate, MTT, and acidified lysis buffer (10% SDS in 10 mM HCl) solution
were purchased in kit format from Roche Molecular biochemical (Mannheim, Germany).
Phosphoramidites were purchased from Glen Research (Sterling, VA).
Oligonucleotide Synthesis
Oligonucleotides were synthesized on an Applied Biosystems 3400 DNA synthesizer using
standard phosphoramidite chemistry. DNA was synthesized with a 5′-dimethoxytrityl
(DMT) protecting group. The oligonucleotides were cleaved from the beads by reaction with
concentrated ammonium hydroxide at 60° C overnight. The resulting free oligonucleotides
were purified by HPLC using a C18 reverse-phase column (Varian, Inc.) on a Hewlett-
Packard 1100 HPLC. The DMT group was removed by reaction with 80% acetic acid for 15
min at ambient temperature. The DMT-free oligonucleotides were precipitated with absolute
ethanol and purified again by HPLC. Positive identification of the oligonucleotides and their
purity were confirmed by MALDI-TOF mass spectrometry. Quantification was performed
on a Beckman DU 7400 spectrophotometer using the extinction coefficients at 260 nm
(ε260) estimated for single-stranded DNA.
Synthesis and Characterization of Metal Complexes
The complexes [Rh(bpy)2(chrysi)]3+, [Rh(HDPA)2(chrysi)]3+, [Rh(NH3)4(chrysi)]3+,
[Rh(DIP)2(chrysi)]3, [Rh(DPAE)2(chrysi)]3+, and [Rh(PrDPA)2(chrysi)]3+ prepared
according to published procedures.22,29,30 [Rh(chrysi)(phen)(NH3)2]Cl3 was prepared from
[Rh(phen)(NH3)4]OTf3 and 5,6-chrysenequinone following the methods described by
Mürner et. al.31 The ligand 1,1- di(pyridin-2-yl)ethanol (DPE) was synthesized according to
published procedures.32
N-alkyl-N-(pyridin-2-yl)pyridin-2-amine (alkyl = methyl or propyl; MeDPA,
PrDPA)—To a slurry of sodium hydride (70 mg, 2.9 mmol) in THF (10 ml) was added
HDPA (500 mg, 2.9 mmol) in 5 ml THF at 0 °C under 1 atm Ar. The reaction was purged
with argon for 15 min, and the appropriate 1-bromoalkane (3.8 mmol) was added dropwise
and warmed to ambient temperature. The reaction was stirred an additional 18 h under argon
at reflux temperature. The reaction mixture was extracted with dilute sodium bicarbonate,
and the aqueous phase was extracted with CH2Cl2 (3 × 40 ml). The organic fractions were
combined and dried over magnesium sulfate, and the solvent was removed in vacuo. 5b was
purified via flash chromatography.
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MeDPA: Yield: 23%. 1H-NMR (CDCl3, 300 MHz): δ 8.35 (d of d, 2H); 7.54 (t, 2H); 7.17
(d, 2H); 6.86 (t, 2H), 3.62 (s, 3H). ESI-MS (cation): m/z calc. 186.1 (M+H+), obs. 186.
PrDPA: Yield: 25%. 1H NMR (CDCl3, 300 MHz): δ 8.34 (d, J = 7.7 Hz, 2H), 7.57 – 7.45
(m, 2H), 7.06 (d, J = 0.7 Hz, 2H), 6.90 – 6.79 (m, 2H), 4.19 – 4.07 (m, 2H), 1.79 – 1.65 (m,
2H), 0.99 – 0.85 (m, 3H) ppm. ESI-MS (cation): m/z calc. 214.1 (M + H+), obs. 214.
[Rh(NH3)4(phzi)]Cl3. [Rh(NH3)6][OTf]3 (0.50 g, 0.77 mmol) and benzo[α]phenazine-5,6-
dione (0.200 g, 0.77 mmol) were dissolved in a 1:5 mixture of water:acetonitrile (500 mL).
A 1M solution of NaOH (1 mL) was added to the yellow solution and the reaction was
allowed to stir at ambient temperature for 45 min, at which time a 1M solution of HCl (1
mL) was added to neutralize the reaction mixture. The acetonitrile was evaporated in vacuo
and the resulting yellow solution was loaded onto a SPE cartridge, eluted with 25%
acetonitrile in 0.1% TFA(aq), and lyophilized to give a yellow solid. The chloride salt can be
obtained from a Sephadex QAE anion exchange column equilibrated with 0.1M MgCl2.
Yield: 0.45 g, 76%. 1H NMR (300 MHz, d6-DMSO): δ 3.79 (s, 6H), 4.48 (d, J = 20.1 Hz, 6
H), 7.92–8.21 (m, 4H), 8.34 (m, 2H), 8.62 (d, J = 7.6 Hz, 1H), 8.96 (d, J =7.8 Hz, 1 H),
13.88 (s, 1H), 13.98 (s, 1H). ESI-MS (cation): m/z calc. 524.07 (M-NH3+TFA+), obs. 523.8.
UV-Vis (H2O, pH 7): 250 nm (36,800 M−1 cm−1), 310 nm (20,800 M−1, cm−1), 340 nm
(23,400 M−1, cm−1).
[Rh(chrysi)(phen)(L)]Cl3 (L= HDPA, MeDPA, PrDPA,)—Rh(chrysi)(phen)(NH3)2]Cl3
(25 mg, 0.02 mmol) was reacted with L (0.022 mmol) in a 4:1 mixture of ethanol:water (10
mL). The bright red solution was refluxed overnight. The solvent was removed in vacuo and
the product was filtered to remove any residue. The filtrate was concentrated on a SPE
cartridge, eluted with 20% acetonitrile in TFA(aq), and lyophilized to give a red solid.
Analytically pure material was obtained from reverse phase HPLC and lyophilized to yield a
dark red solid. The chloride salt can be obtained from a Sephadex QAE anion exchange
column equilibrated with 0.1M MgCl.
[Rh(chrysi)(phen)(HDPA)]Cl3 Yield: 28%. ESI-MS (cation): m/z calc 708.14 (M-2H+),
obs. 708.2. UV-Vis (H2O, pH 7): 303 nm (57000 M−1 cm−1), 391 nm (10,600 M−1, cm−1)
[Rh(chrysi)(phen)(MeDPA)]Cl3 Yield: 32%. ESI-MS (cation): m/z calc. 722.15 (M- 2H+)
361.6 (M-H2+), obs. 722, 362.
[Rh(chrysi)(phen)(PrDPA)]Cl3 Yield: 22%. ESI-MS: calc. 750.18 (M-2H+), 375.6 (M-
H2+), obs. 750, 376.
[Rh(chrysi)(phen)(DPE)]Cl3—A 125 mL round-bottomed flask was charged with
[Rh(chrysi)(phen)(NH3)2]TFA3 (62.0 mg, 0.068 mmol) and DPE (25.6 mg, 0.128 mmol) in
ethanol (50 mL) to give a red solution. The reaction was heated to reflux (80° C) and stirred
for 48 h. The ethanol solution was evaporated to dryness and dissolved in 0.1% TFA(aq)(50
mL). The red solution was loaded onto a SPE cartridge and rinsed with copious amounts of
0.1% TFA(aq). The SPE cartridge was eluted with 10% acetonitrile in 0.1% TFA(aq) and
fractions were collected. The fractions containing product were identified by HPLC,
combined, and lyophilized. The chloride salt can be obtained from a Sephadex QAE anion
exchange column equilibrated with 0.1M MgCl. Yield: 17 mg. ESI-MS (cation): m/z calc.
737.15 (M-2H+), 369.1 (M-H2+), obs. 737, 369. UV-Vis (H2O, pH 7): 272 nm (59800 M−1
cm−1), 303 nm (18,400 M−1, cm−1), 440 nm (5,400 M−1, cm−1).
Photocleavage Competition Titrations
The oligonucleotide was 32P-labeled at the 5′-end by incubating DNA with 32P-ATP and
polynucleotide kinase (PNK) at 37°C for 2 h, followed by purification using gel
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electrophoresis. A small amount of the labeled DNA (less than 1% of the total amount of
DNA) was added to 2 μM DNA in 100 mM NaCl, 20 mM NaPi, pH 7.1 buffer. The DNA
hairpin was annealed by heating at 90°C for 10 min and cooling slowly to ambient
temperature over a period of 2 h. Racemic solutions of non-photocleaving rhodium complex
ranging from nanomolar to micromolar concentration, as well as a 4 μM
[Rh(bpy)2(chrysi)]3+ solution were made in Milli-Q water. Annealed 2 μM DNA (10 μL), 4
μM [Rh(bpy)2(chrysi)]3+ (5 μL), and 5 μL of non-photocleaving Rh solution at each
concentration were mixed in a microcentrifuge tube and incubated at 37 °C for 10 min. A
light control (ØRh), in which the DNA was mixed with 10 μL of water and irradiated, and a
dark control (Øhν), in which the DNA was mixed with the highest concentration of rhodium
complex without irradiation, were also prepared. The samples were then irradiated on an
Oriel (Darmstadt, Germany) 1000-W Hg/Xe solar simulator (340–440 nm) for 5 min. The
irradiated samples were dried and electrophoresed in a 20% denaturing polyacrylamide gel.
The gel was then exposed to a phosphor screen, and the relative amounts of DNA in each
band were quantitated by phosphorimagery (ImageQuant).
Binding Constant Determination
The fraction of DNA cleaved in each lane on the gel (See Figure S1 for a typical
autoradiogram) was normalized and plotted against the log of the concentration of rhodium
complex. At least three photocleavage titrations were carried out for each racemic metal
complex. The pooled data were fit to a sigmoidal curve using OriginPro 6.1 (See Figure S2).
The resulting midpoint value (i.e., the log of [rhodium complex] at the inflection point of the
curve) was converted to units of concentration ([Rh50%]). The binding and dissociation
constants of the non-photocleaving complex were calculated by solving simultaneous
equlibria involving DNA, [Rh(bpy)2(chrysi)]3+, and the complex in question in Mathematica
6.0.
Cell Culture
HCT116N and HCT116O cells were grown in RPMI medium 1640 supplemented with: 10%
FBS; 2 mM L-glutamine; 0.1 mM nonessential amino acids; 1 mM sodium pyruvate; 100
units/mL penicillin; 100 μg/mL streptomycin; and 400 μg/mL Geneticin (G418). Cells were
grown in tissue culture flasks (Corning Costar, Acton, MA) at 37 °C under 5% CO2 and
humidified atmosphere.
Cellular Proliferation ELISA
HCT116N and HCT116O cells were plated in 96-well plates at 2000 cells/well and allowed
24 h to adhere. The cells were then incubated with rhodium for the concentration and
durations specified. For incubations less than 72 h, the Rh-containing media was replaced
with fresh media, and the cells were grown for the remainder of the 72 h period. Cells were
labeled with BrdU 24 h before analysis. The BrdU incorporation was quantified by antibody
assay according to established procedures.33 Cellular proliferation was expressed as the ratio
of the amount of BrdU incorporated by the treated cells to that of the untreated cells.
MTT Cytotoxicity Assay
Cytotoxicity assays were performed as described in the literature.34 HCT116N and
HCT116O cells were plated in 96-well plates at 50,000 cells/well and incubated with
rhodium for the durations specified. After rhodium incubation, cells were labeled with MTT
for 4 h at 37°C under 5% CO2 and humidified atmosphere. The resulting formazan crystals
were dissolved with solubilizing reagent purchased from Roche according to the
manufacturer’s instructions. The dissolved formazan was quantified as the absorbance at
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570 nm minus the background absorbance at 690 nm. Percent viability was determined as
the ratio of the amount of formazan in the treated cells to that of the untreated cells.
Nuclear Isolation Protocol
Approximately 10 million HCT116N/O cells were harvested from adherent culture by
trypsinization, washed with cold PBS, and resuspended in 1 mL hypotonic buffer (20 mM
TrisHCl pH 7.4, 10 mM NaCl, 3 mM MgCl2). The resulting suspension was incubated on
ice for 15 min. 50 μL of a 10% NP-40 solution was added to the solution and immediately
followed by vortexing at the highest setting for 10 seconds. The solution was then
centrifuged at 3,000g for 10 min. The supernatant was discarded and the pellet saved as the
nuclear fraction.
Mitochondrial Isolation Protocol
The followed protocol is an adaptation of that used by Ahmad, et al.35 Approximately 20
million HCT116N/O cells were harvested from adherent culture by trypsinization, washed
with cold PBS, and resuspended in 500 μL mitochondrial extraction buffer (200 mM
mannitol, 68 mM sucrose, 50 mM pipes, 50 mM KCl, 5 mM EGTA, 2 mM MgCl2, 1 mM
DTT, protease inhibitors). The resulting suspension was incubated on ice for 20 min, then
homogenized by 35 passes through a 21 gauge needle and 1-mL syringe. The resulting
lysate was centrifuged at 150g for 5 min. The supernatant was then transferred to a new
microcentrifuge tube and centrifuged for an additional 10 min at 14,000g. The supernatant
was discarded and the pellet saved as the mitochondrial fraction.
ICP-MS Assay for Whole-Cell Rhodium Levels
HCT116O cells were plated at 1×106 cells/well in a 6 well plate. The cells were allowed 24
h to adhere, then treated with 10 μM of rhodium complex. After the appropriate amount of
time, the media was decanted, the cell monolayer washed with 3 mL PBS, and the cells
lysed with 800 μL of 1% SDS. The cell lysate was further lysed by sonication on a Qsonica
Ultrasonic processor for 10 sec at 20% amplitude. 750 μL of the lysate was then combined
with 750 μL of a 2% HNO3 (v/v) solution, while the remainder of the lysate was quantified
for protein by a bicinchoninic assay (BCA).36 The 1% HNO3 solution was analyzed for
rhodium content on an HP-4500 ICP-MS unit. Rhodium counts were normalized to the
amount of protein determined from the BCA analysis (to obtain ng [Rhodium]/mg [protein]
values). Standard errors for three independent experiments are shown. The experiment was
repeated with HCT116N cells only to verify similar uptake of rhodium by the two cell lines.
ICP-MS Assay for Nuclear Rhodium Levels
HCT116O cells were plated at 10 × 106 cells/plate in culture flasks and allowed 24 h to
adhere. The cells were then treated with 10 μM of rhodium complex for 24 h, harvested by
trypsinization, and washed with PBS. The nuclear isolation protocol was then performed on
the cells. The resulting pellet was resuspended in 800 μL Milli-Q water and lysed by
sonication on a Qsonica Ultrasonic processor for 10 sec at 40% amplitude. 750 μL of the
lysate was then combined with 750 μL of a 2% HNO3 (v/v) solution, while the remainder of
the lysate was quantified for protein by a bicinchoninic assay (BCA).36 The resulting 1%
HNO3 solution was analyzed for rhodium content on an HP-4500 ICP-MS unit. Rhodium
counts were normalized to the amount of protein determined from the BCA analysis (to
obtain ng [Rhodium]/mg [protein]). The protein content was converted to number of nuclei
by the conversion factors 3.28 × 10−8 mg [nuclear protein]/nuclei (found by counting cells
or nuclei with a hemacytometer followed by lysing and protein quantification). The rhodium
concentrations were then divided by nuclei density to obtain ng of rhodium per nucleus.
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Standard errors for three independent experiments are shown. The experiment was repeated
with HCT116N cells to verify similar uptake of rhodium by the two cell lines.
ICP-MS Assay for Mitochondrial Rhodium Levels
HCT116O cells were plated at 15 × 106 cells/plate in culture flasks and allowed 24 h to
adhere. The cells were then treated with 10 μM of rhodium complex for 24 h, harvested by
trypsinization, and washed with PBS. The mitochondrial isolation protocol was then
performed on the cells. The resulting pellet was resuspended in 800 μL Milli-Q water and
lysed by sonication on a Qsonica Ultrasonic processor for 10 sec at 40% amplitude. 750 μL
of the lysate was then combined with 750 μL of a 2% HNO3 (v/v) solution, while the
remainder of the lysate was quantified for protein by a bicinchoninic assay (BCA). The
resulting 1% HNO3 solution was analyzed for rhodium content on an HP-4500 ICP-MS unit.
Rhodium counts were normalized to the amount of protein determined from the BCA
analysis (to obtain ng [Rhodium]/mg [protein] values). Standard errors for three independent
experiments are shown. The experiment was repeated with HCT116N cells for one time
point only to verify similar uptake of rhodium by the two cell lines.
RESULTS
Binding Affinities for Metal Complexes at Single Base Mismatches
The binding constants of the various rhodium metalloinsertors at a CC mismatch in a 29-mer
DNA hairpin with the sequence 5′-GGCAGGCATGGCTTTTTGCCATCCCTGCC-3′
(underline denotes the mismatch) were measured. The hairpin sequence allows cleavage site
determination on either strand around the mismatch site. All newly synthesized rhodium
complexes promote relatively little DNA cleavage upon irradiation, and as such their
binding affinities were determined through binding competition titrations with 1 μM rac-
[Rh(bpy)2(chrysi)]3+, which does cleave DNA upon irradiation.10–12 A representative
photocleavage titration can be found in Figure S1. The degree of photocleavage can be
plotted against the log([Rh]) and fit to a sigmoidal curve (See Figure S2). On the basis of the
binding constant of [Rh(bpy)2(chrysi)]3+, the binding constants of all subsequent complexes
are then determined by solving simultaneous equilibria at the inflection point of the
photocleavage titration curve. The results, along with those of all previously reported
compounds,22,30 are shown in Figure 1. Interestingly, despite the variance in both the
ancillary ligands and number of hydrogen-bond donors, all compounds (except the
extremely bulky [Rh(DIP)2(chrysi)]3+) exhibit binding affinities within essentially the same
order of magnitude, varying from 2.3 × 106 M−1 to 4.4 × 107 M−1.
Quantitation of Inhibition of Cellular Proliferation using an Enzyme-Linked Immunosorbent
Assay (ELISA)
An ELISA for DNA synthesis was used to quantify the effects of the metalloinsertors on the
proliferation of HCT116N cells (MMR-proficient) and HCT116O cells (MMR-deficient).
Both cell lines were incubated with 0–25 μM of each compound (except
[Rh(DIP)2(chrysi)]3+ and [Rh(chrysi)(phen)(DPE)]3+, which were both administered at 0–5
μM concentrations due to increased potency). Incubations were performed for 1, 3, 6, 12 or
24 h. After the incubations, the medium containing Rh was replaced with fresh medium, and
the cells were grown for the remainder of the 72 h period. The extent of cellular proliferation
is expressed as the ratio of BrdU incorporated by the rhodium-treated cells as compared to
untreated controls. Furthermore, we define differential inhibition as the difference in BrdU
incorporation between the HCT116N and HCT116O cells. Figure 2 shows representative
data for [Rh(chrysi)(phen)(DPE)]3+. Data for all other compounds can be found in Figures
S3–S12. Very little to no activity is seen for any of the compounds at 1 or 3 hour incubation
times (data not shown).
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Figure 3 summarizes the ELISA results for all compounds tested at 10 μM rhodium
concentration and 24 h of incubation (Except [Rh(DIP)2(chrysi)]3+, which is shown at 2
μM), as these are the same conditions used for all ICP-MS experiments.22,30,37 There are
four compounds with high selectivity for the MMR-deficient HCT116O cells
([Rh(NH3)4(phzi)]3+, [Rh(chrysi)(phen)(DPE)]3+, [Rh(DPAE)2(chrysi)]3+, and
[Rh(HDPA)2(chrysi)]3+, all shownin different shades of blue), displaying differential
inhibitions of 63 ± 5%, 55 ± 3%, 55 ± 3%, and 52 ± 2%, respectively. [Rh(chrysi)(phen)
(HDPA)]3+ and [Rh(bpy)2(chrysi)]3+ exhibit modest selectivity with differential inhibitions
of 27 ± 2% and 8 ± 2% at 24 h (shown in green in Figure 3). It should be noted that at longer
incubation times the differential inhibition of [Rh(bpy)2(chrysi)]3+ increases.22 [Rh(chrysi)
(phen)(MeDPA)]3+, also shown in green, exhibits delayed biological activity. At 24 h
incubation times, this complex does not display significant inhibition of DNA synthesis
toward either cell line. The remaining compounds ([Rh(chrysi)(phen)(PrDPA)]3+,
[Rh(PrDPA)2(chrysi)]3+and [Rh(DIP)2(chrysi)]3+, shown in red) exhibit no selectivity for
the MMR-deficient HCT116O cell line, and inhibit DNA synthesis similarly in both cell
lines. It should be noted that none of the complexes studied show a differential inhibition
favoring the HCT116N cell line, although that is the common result for many DNA
damaging agents.
Many of these compounds exhibit accelerated activity in the ELISA assay, displaying
substantial differential inhibition of DNA synthesis towards the HCT116O cell line at 6 or
12 h incubation times. Motivated by the previous observation that rhodium metalloinsertors
which display accelerated activity in the ELISA assay exhibit preferential cytotoxicity
towards the MMR-deficient HCT116O cell line,23 we chose also to test all compounds for
cytotoxicity in the MTT assay.
MTT Cytotoxicity Assay
The cytotoxic effects of all compounds were determined by MTT assay.34 Briefly, reduction
of the MTT reagent by metabolically active cells leads to the production of formazan, which
can then be dissolved in acidified SDS to produce a characteristic absorbance at 570 nm.
This absorbance reflects the percentage of metabolically active cells in each sample.
HCT116N and HCT116O cells were plated and treated with the various rhodium complexes
at the concentrations indicated in Figure 4 for 24, 48, or 72 h. Percent viability is defined as
the ratio of the amount of formazan in the treated cells to that in the untreated cells, and
differential cytotoxicity is defined as the difference between the percent viabilities of the
two cell lines. The 72 h results are shown in Figure 4. These results are consistent with the
ELISA assay results. The same four compounds that show the best differential inhibition of
DNA synthesis in the ELISA assay ([Rh(NH3)4(phzi)]3+, [Rh(chrysi)(phen)(DPE)]3+,
[Rh(DPAE)2(chrysi)]3+, and [Rh(HDPA)2(chrysi)]3+) exhibit highly selective cytotoxicities
towards the MMR-deficient HCT116O cell line, 72 ± 4%, 69 ± 3%, 47 ± 1%, and 55 ± 1%,
respectively (at their respective optimal concentrations). The compounds that exhibit
delayed activity in the ELISA assay ([Rh(chrysi)(phen)(MeDPA)]3+ and
[Rh(bpy)2(chrysi)]3+) do not display significant cytotoxicity toward either cell line in the
MTT assay, consistent with previous observations.23 The remaining compounds
([Rh(chrysi)(phen)(HDPA)]3+, [Rh(chrysi)(phen)(PrDPA)]3+, [Rh(PrDPA)2(chrysi)]3+, and
[Rh(DIP)2(chrysi)]3+) exhibit either modest or no selective cytotoxicity towards the
HCT116O cell line, consistent with their activities in the ELISA assay.
Despite our previous results22 that rhodium metalloinsertors’ biological activity correlates
directly with their binding affinities, the metalloinsertors discussed herein have similar DNA
binding affinities (except [Rh(DIP)2(chrysi)]3+), yet display biological activities that vary
drastically. ICP-MS studies were undertaken in order to determine if the cellular uptake and
distribution of these rhodium metalloinsertors could explain their variation in activities.
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ICP-MS Assay for Whole-Cell Rhodium Levels
HCT116O cells were treated with 10 μM of each rhodium complex (except
[Rh(DIP)2(chrysi)]3+, which was administered at 2 μM) for 1, 3, 6, 12, or 24 h. Whole cell
lysates were analyzed for rhodium levels by ICP-MS and normalized to protein content
(Figure 5). The experiment was repeated with HCT116N cells at 24 h to confirm that
cellular uptake is not different for the HCT116 O versus N cells and to verify consistency in
trends among the ten compounds.
There seem to be a variety of modes of uptake at play. The most lipophilic compounds,
[Rh(chrysi)(phen)(PrDPA)]3+, [Rh(PrDPA)2(chrysi)]3+, and [Rh(DIP)2(chrysi)]3+, exhibit
gradual uptake into the HCT116O cells, suggestive of passive diffusion. This is consistent
with previous studies conducted on luminescent [Ru(L)2dppz]2+ (dppz = dipyrido[3,2-α:2′,
3′-c]phenazine) analogues, demonstrating cellular accumulation through passive diffusion,
facilitated by the negative potential difference across the cell membrane.38,39 The two
compounds that exhibit delayed biological activity in the ELISA assay ([Rh(chrysi)(phen)
(MeDPA)]3+ and [Rh(bpy)2(chrysi)]3+) exhibit no increase in cellular rhodium levels after
initial uptake at 1 hour. Furthermore, the two compounds with HDPA ligands exhibit an
enhanced cellular uptake despite reduced lipophilicities. They show a very high initial
uptake, followed by a slight increase over the next 23 hours. The MeDPA compound does
not exhibit the increase in uptake that we had expected, given its enhanced lipophilicity
compared to the HDPA analog: This suggests a completely different mechanism of uptake
for the HDPA complex. The two compounds with PrDPA ligands do exhibit enhanced
uptakes compared to their respective HDPA analogs at 24 hr, but not nearly to the degree we
would have expected based on lipophilicities. However, both the PrDPA compounds appear
to be taken up through passive diffusion, unlike the HDPA compounds. Perhaps the fact that
the HDPA ligand has the potential to form hydrogen bonds in cellulo is important to its path
into the cell. The compounds that exhibit the highest selectivities in the biological assays
([Rh(chrysi)(phen)(DPE)]3+, [Rh(DPAE)2(chrysi)]3+, and [Rh(NH3)4(phzi)]3+) by no means
have the highest overall rhodium levels. In fact, all three of them have among the lowest
amount of rhodium uptake into cells.
ICP-MS Assay for Nuclear Rhodium Levels
HCT116O cells were treated with 10 μM of each rhodium complex (except
[Rh(DIP)2(chrysi)]3+, which was administered at 2 μM) for 24 h. The cells were harvested
by trypsinization and the nuclei were isolated. Nuclear rhodium levels were determined by
ICP-MS and normalized to protein content. The protein content was converted to number of
nuclei by the conversion factors 3.28 × 10−8 mg [nuclear protein]/nuclei (found by counting
cells or nuclei with a hemacytometer followed by lysing and protein quantification). The
rhodium concentrations were then divided by nuclei density to obtain ng of rhodium per
nucleus. The process was repeated with HCT116N cells to confirm that the two cell lines
behave similarly and to verify consistency in trends among the ten compounds. These
numbers can be used to estimate nuclear concentrations by approximating the nucleus of a
HCT116O cell as a sphere with radius 4 μm.40 The approximate nuclear rhodium
concentrations, so determined, are reported in Figure 1.
As can be seen in Figure 6, there is little correlation between cell-selective activity and
nuclear rhodium concentration. In fact, all nuclear rhodium concentrations except for that of
[Rh(DPAE)2(chrysi)]3+ are within a factor of two of each other and hardly vary among the
10 compounds. When we approximate the nuclear concentrations in molarity of the 10
compounds, all compounds are present in the nucleus at concentrations on the order of 10−5
to 10−4 M. These concentrations are all more than 2 orders of magnitude higher than the
binding affinities for in vitro mismatch detection (yet below non-specific DNA binding
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levels). Thus even estimating the error on these numbers to be an order of magnitude, all
compounds are present in the nucleus at concentrations sufficient for mismatch binding.
ICP-MS Assay for Mitochondrial Rhodium Levels
HCT116O cells were treated with 10 μM of each rhodium complex (except
[Rh(DIP)2(chrysi)]3+, which was administered at 2 μM) for 24 h. The cells were harvested
by trypsinization, the mitochondria were isolated, and the rhodium levels were analyzed by
ICP-MS and normalized to protein content. The results are summarized in Figure 6
alongside the nuclear concentrations. The fact that the three compounds with the most cell-
selective biological activity ([Rh(NH3)4(phzi)]3+, [Rh(chrysi)(phen)(DPE)]3+, and
[Rh(DPAE)2(chrysi)]3+, shown in blue) have the lowest mitochondrial rhodium
accumulation, 152 ± 3 ng [Rh]/mg [mitochondrial protein], 106 ± 7 ng [Rh]/mg
[mitochondrial protein], and 141 ± 8 ng [Rh]/mg [mitochondrial protein], respectively, is
striking. This correlation indicates that the biological target of our rhodium metalloinsertors
is genomic DNA rather than mitochondrial DNA.
Furthermore, the three compounds that exhibit no selectivity for the MMR-deficient
HCT116O cell line in both biological assays ([Rh(chrysi)(phen)(PrDPA)]3+,
[Rh(PrDPA)2(chrysi)]3+, and [Rh(DIP)2(chrysi)]3+, shown in red) display the highest levels
of mitochondrial rhodium accumulation, 560 ± 30 ng [Rh]/mg [mitochondrial protein], 1260
± 150 ng [Rh]/mg [mitochondrial protein] and 740 ± 70 ng [Rh]/mg [mitochondrial protein],
respectively. This result points to mitochondrial targeting as responsible for the promiscuous
biological activity associated with these three compounds that detracts from the cell-
selective activity. The two HDPA-containing compounds stray from the trends observed
with the other eight compounds.
DISCUSSION
Variations in Complexes Synthesized
The compounds displayed in Figure 1 were synthesized initially in order to investigate the
biological effects of varying the lipophilicity of the metalloinsertor. [Rh(HDPA)2(chrysi)]3+
has been shown to exhibit accelerated biological activity, as well as an enhanced selectivity
for the MMR-deficient HCT116O cell line compared to that expected based solely on its
binding affinity.22,23 By varying L in [Rh(chrysi)(phen)(L)]3+ from HDPA to MeDPA to
PrDPA, we sought to examine the effect that changes in lipophilicity have on uptake and to
determine if the proton associated with the HDPA ligand, which is not present in other
compounds examined, might play some role in the enhanced activity and uptake of
[Rh(HDPA)2(chrysi)]3+. The DPE ligand is an analog of HDPA, but without the amine
nitrogen which is capable of inverting its geometry. This therefore affords an analog of
[Rh(chrysi)(phen)(HDPA)]3+ with a less flexible dipyridyl ligand that still has the potential
to form hydrogen bonds. The chrysi analog of [Rh(NH3)4(phzi)]3+ was shown to exhibit
excellent differential activity in the ELISA assay,22 and therefore its phzi analog was
synthesized both in the hopes of making a compound with increased efficacy,13 and to look
at the biological effects of decreasing lipophilicity. The compounds [Rh(DPAE)2(chrysi)]3+
and [Rh(PrDPA)2(chrysi)]3+ were made as a matched pair to look at the biological effects of
small structural changes to the ancillary ligands.
Surprisingly, all compounds exhibited binding affinities within the same order of magnitude
(except [Rh(DIP)2(chrysi)]3+, which was included in the study as a reference compound
with extreme lipophilicity, poor binding to mismatches, and no selectivity in our biological
assays). The differences among these nine compounds in the ELISA and MTT assays
therefore arise from primarily biological effects rather than mismatch binding.
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For all compounds, the cytotoxic effects seen in the MTT assay reflect the antiproliferative
activity seen in the ELISA assay. Both compounds that exhibit delayed activity in the
ELISA assay, [Rh(chrysi)(phen)(MeDPA)]3+ and [Rh(bpy)2(chrysi)]3+, do not show any
significant cytotoxicity in the MTT assay. Furthermore, the four compounds with the largest
differential inhibitions in the ELISA assay, [Rh(NH3)4(phzi)]3+, [Rh(chrysi)(phen)(DPE)]3+,
[Rh(DPAE)2(chrysi)]3+, and [Rh(HDPA)2(chrysi)]3+, also show the largest differential
cytotoxicities by the MTT assay. Finally, the three compounds with no differential activity
in the ELISA assay, [Rh(chrysi)(phen)(PrDPA)]3+, [Rh(PrDPA)2(chrysi)]3+, and
[Rh(DIP)2(chrysi)]3+, also show no differential cytotoxicity in the MTT assay. It is
important to distinguish the absence of differential activity, where the compound shows no
selectivity for one cell line over the other and affects both cell lines to the same degree,
versus the absence of all activity, where the compound shows no appreciable biological
effect on either cell line.
Significantly, the biological activities of these compounds vary dramatically despite their
similar binding affinities. Interestingly, the effect of appending a lipophilic alkyl chain to the
back of the HDPA ligand either significantly slows down all activity, as with the MeDPA
derivative, or instead abolishes the selectivity of the compound for the MMR-deficient
HCT116O cell line, as with the PrDPA derivatives. While the mechanism of inhibition is not
yet fully understood, one possible scenario is protein recognition of the metalloinsertor-
mismatch complex, generating a covalent protein-DNA lesion. Bulky tethers off the back of
the metalloinsertor may inhibit the formation of such a lesion, leading to the aforementioned
observations. Yet another explanation for the results might be that the increased lipophilicity
of the metalloinsertor enhances uptake into the cell but also alters the subcellular
localization of the complex once it has entered the cell. This altered subcellular localization
could be the reason for the lack of selectivity of the compound for one cell line over the
other. Indeed, the least lipophilic compounds have the most selective biological activity,
while the more lipophilic compounds exhibit no selective biological activity.
Metalloinsertor Uptake and Nuclear Accumulation
Table 1 displays qualitative nuclear and mitochondrial uptake properties, as well as the
presence or absence of cell-selective biological activity for all ten metalloinsertors.
Importantly, the biological effects seen in both assays can be explained by the subcellular
localization of the metalloinsertors. If passive diffusion were the dominant mode of cellular
uptake for these metalloinsertors,38,39 the more lipophilic compounds would be expected to
have increased cellular uptake. And indeed, except for the HDPA compounds, the most
lipophilic compounds do exhibit the greatest cellular accumulation. However, the more
liphophilic compounds are in general associated with little differential biological activity;
high accumulations of these metalloinsertors are toxic.
By altering L in [Rh(chrysi)(phen)(L)]3+ from HDPA to MeDPA to PrDPA, we do not
observe an increase in uptake. In fact, the HDPA complex seems to show enhanced uptake
in comparison with those that are more lipophilic. Furthermore, both compounds that
possess HDPA ligands display both enhanced and accelerated uptake. This is likely due to
additional uptake pathways facilitating the influx of complexes containing HDPA. Indeed,
several bis(cyclometalated) iridium(III) polypyridine complexes have been shown to employ
more than one mechanism of uptake,41 and this may be the case for several of our
metalloinsertors. In comparing [Rh(PrDPA)2(chrysi)]3+ to [Rh(DPAE)2(chrysi)]3+, it
appears that by altering the methyl group of PrDPA to an alcohol, uptake is decreased by a
factor of four, yet only the DPAE compound has cell-selective activity. Lastly, the most
polar compound, [Rh(NH3)4(phzi)]3+, displays a peak in uptake at 3 hours, after which
cellular rhodium levels seem to decrease steadily. This is most likely caused by an efflux
mechanism, that is, pumping the complex out of the cell. The ATP-binding cassette protein
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ABCG2 has been reported to be overexpressed in HCT116 cells,42 is known to exhibit
substrate promiscuity,43 and may be responsible. Contrary to what would be expected, three
of the four compounds with high activity have among the lowest cellular uptake at 24 hours,
while the three compounds with no cell-selective activity have among the highest cellular
uptake at 24 hours. It appears as though increased cellular uptake is actually detrimental to
the unique cell-selective behavior of our metalloinsertors.
Significantly, the nuclear rhodium concentrations vary only slightly among the ten
compounds. Importantly, by approximating the nucleus of an HCT116O cell as a sphere
with diameter 8 μm,40 all of our metalloinsertors are present in the nucleus at sufficient
concentrations for mismatch binding, given their in vitro binding affinities (See Figure 1).
Moreover, all metalloinsertors are below non-specific DNA binding concentrations, which
precludes non-specific DNA binding as a possible cause of the non-selective toxicity seen
with 3 of our metalloinsertors. The only difference between the two cell lines is the presence
of a functional copy of the MLH1 gene in the HCT116N cell line, which encodes for a
MMR protein found in the nucleus.44 Therefore, any interactions the rhodium complexes
have with the cell that are not associated with the nucleus may account for their nonspecific
biological activity. Consequently, if nuclear DNA were the only cellular target for these
metalloinsertors, then all compounds should exhibit similar differential activity due to their
similar nuclear concentrations. However, these metalloinsertors could also interact with
mitochondrial DNA, or become sequestered in lipid membranes throughout the cell
(including the nuclear membrane, which would cause the nuclear rhodium concentration of
such a complex to appear higher than it actually is), both of which would result in
nonspecific biological activity.
Mitochondrial Accumulation of Rhodium Metalloinsertors
Importantly, the metalloinsertors that display highly cell-selective biological activity are
generally associated with lower mitochondrial rhodium accumulation (Figure 6, complexes
shown in blue), while the metalloinsertors that display non-selective toxicity show larger
mitochondrial rhodium accumulation (Figure 6, complexes shown in red). These
observations suggest that it is nuclear DNA targeting of our metalloinsertors that is
responsible for their cell-selective biological activities rather than mitochondrial DNA
targeting.
The two compounds [Rh(DPAE)2(chrysi)]3+ and [Rh(PrDPA)2(chrysi)]3+ exhibit this
phenomenon quite simply.30 The only structural difference between the two compounds is
the substitution of the methyl group of the PrDPA ligand for a primary alcohol in the DPAE
ligand. While this substitution is structurally minute, the consequences of such a substitution
are extreme from a biological standpoint. This substitution causes a large increase in polarity
for the DPAE complex, as can be quantified by a decrease in the logP values from −1.0 to
−1.5.30 Significantly, this increase in polarity is accompanied by an increase in cell-selective
biological activity. While the more lipophilic [Rh(PrDPA)2(chrysi)]3+complex exhibits no
selectivity for the MMR-deficient cell line, the more polar [Rh(DPAE)2(chrysi)]3+ complex
is highly selective for the MMR-deficient line over the MMR-proficient line. Furthermore,
this small structural change results in dramatic changes in uptake and localization of the
compounds. While the more lipophilic [Rh(PrDPA)2(chrysi)]3+complex has about a four-
fold greater uptake into the cell than the polar [Rh(DPAE)2(chrysi)]3+ complex, it exhibits a
ten-fold greater mitochondrial accumulation than the DPAE complex, and only a two-fold
greater nuclear accumulation. This suggests that the non-selective behavior of
[Rh(PrDPA)2(chrysi)]3+ is caused by increased mitochondrial accumulation.
It should be noted, however, that mitochondrial accumulation is not always associated with
non-selective toxicity. The presence of the HDPA ligand enhances and accelerates uptake
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significantly, and even leads to increased mitochondrial accumulation, yet complexes
containing HDPA show high selective biological activitites. In fact, it has recently been
reported that changes in polarity can affect whether mitochondria-targeted peptides simply
accumulate in the mitochondrial matrix or disrupt the mitochondrial membrane activity and
result in apoptosis.45
General Implications for Design
This work supports the hypothesis that nuclear DNA mismatch binding is responsible for the
unique cell-selective biological activity of our rhodium metalloinsertors. Indeed, out of ten
compounds studied, all ten exhibit sufficient nuclear uptake for mismatch binding.
Furthermore, the fact that the three compounds that are not selective for the MMR-deficient
cell line have enhanced mitochondrial accumulation indicates that mitochondrial mismatch
DNA targeting is not responsible for cell-selective behavior. As the only difference between
the two cell lines is a functional copy of the MLH1 gene, a gene which encodes for a nuclear
MMR protein, the cell-selective behavior of our metalloinsertors must be related to this
MMR deficiency. As the mitochondria are the location of oxidative phosphorylation, where
reactive oxygen species are unavoidably formed as byproducts, mitochondrial DNA has
higher levels of oxidative damage than nuclear DNA.46 While these DNA defects could very
well be targets of our metalloinsertors, mtDNA repair pathways do exist,47 and in most
cases are distinct from their nuclear counterparts.48 Specifically, the nuclear MMR proteins
MSH2, MSH3, MSH6, and MLH1 have been shown to be absent from the mitochondria.49
The targeting of defects in mitochondrial DNA therefore cannot be responsible for the
unique cell-selective behavior of our metalloinsertors. Instead, mitochondrial uptake appears
to be associated with nonspecific toxicity.
In this work, all compounds tested are present in the nucleus at sufficient concentrations for
mismatch detection. However, the more liphophilic compounds, which display enhanced
uptake into the cells, tend to localize more in the mitochondria, thus giving rise also to
nonspecific biological activity. While the more polar compounds ([Rh(NH3)4(phzi)]3+,
[Rh(chrysi)(phen)(DPE)]3+, and [Rh(DPAE)2(chrysi)]3+) do not have the largest amount of
cellular rhodium, there is consequently a smaller amount of rhodium in the mitochondria.
This, coupled with sufficient nuclear rhodium for mismatch binding, gives rise to high
MMR-deficient cell-selective biological activities for these three compounds. It seems that
by increasing lipophilicity in an effort to increase uptake via passive diffusion, the
subcellular localization is altered, leading to a larger amount of cellular rhodium residing in
the mitochondria and less selectivity for the MMR-deficient cell line. This tradeoff in uptake
for selectivity is in contrast to current strategies to improve the efficacy of cisplatin by
increasing uptake of the drug.50,51 More generally, these results highlight that the relative
accumulation of complex in different organelles needs to be considered, not simply cellular
accumulation.
Most importantly, these data support the notion that the cell-specific activity we observe is
caused by nuclear DNA mismatch targeting by our metalloinsertors. This exciting new result
gives us key information in designing the next generation of rhodium metalloinsertors as
cell-specific chemotherapeutics.
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Figure 1.
Chemical structures, binding affinities for CC mismatches, and approximated nuclear
concentration of all compounds studied. Note all compounds are shown with both immines
fully protonated; pKa’s of the immine protons vary among complexes and thus the
protonation state of the inserting ligand will vary at physiological pH among the complexes.
Binding affinities for [Rh(DIP)2(chrysi)]3+, [Rh(HDPA)2(chrysi)]3+, [Rh(bpy)2(chrysi)]3+,
[Rh(DPAE)2(chrysi)]3+, and [Rh(PrDPA)2(chrysi)]3+ are previously reported.10,22,36 All
other compounds’ DNA binding affinities were measured on the 29mer hairpin 5′-
GGCAGGCATGGCTTTTTGCCATCCCTGCC-3′ (underline denotes the mismatch) in a
competition assay through photocleavage by [Rh(bpy)2chrysi]3+. Samples were irradiated
and electrophoresed through a 20% denaturing PAGE gel, and the percent of DNA
cleavaged at each concentration was plotted as a function of log [Rh]. The data were fitted to
a sigmoidal curve, and KB values were determined by calculating the concentration of
rhodium at the inflection points of the curve and solving simultaneous equilibria. To
determine nuclear rhodium concentrations, HCT116O cells were incubated in media
containing 10 μM of each rhodium complex (except [Rh(DIP)2(chrysi)]3+, which was
administered at 2 μM) for 24 h. The cells were harvested by trypsinization and the nuclei
isolated. Rhodium content was quantified by ICP-MS first normalized to number of nuclei,
then divided by the volume of the nucleus of a HCT116O cell, which was approximated as a
sphere with radius 4 μm.46 It is important to note that while the structures all illustrate the Δ
isomers, all experiments were done with racemic mixtures.
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Figure 2.
Inhibitory effects of [Rh(chrysi)(phen)(DPE)]3+as a function of incubation time on cellular
proliferation. Shown are plots of BrdU incorporation (a measure of DNA synthesis and
therefore cellular proliferation) normalized to the BrdU incorporation of untreated cells as a
function of rhodium concentration. Standard error bars for five trials are shown. MMR-
proficient HCT116N cells (green) and MMR-deficient HCT116O cells (red) were plated and
allowed 24 h to adhere before incubation with 0–5 μM for 1, 3, 6, 12, or 24 h. At the end of
the incubations, the medium containing rhodium was replaced with fresh medium for the
remainder of the 72 h period, followed by ELISA analysis. BrdU was added to the medium
24 h prior to analysis. 1 and 3 h plots are not shown, as no activity was observed.
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Figure 3.
Inhibitory effects of rhodium metalloinsertors as a function of metalloinsertor identity. The
percent differential inhibition is defined as the difference of the normalized percentages of
cellular proliferation between the two cell lines, HCT116O versus HCT116N. ELISA
analyses were performed as in Figure 2. Cells were incubated with 10 μM rhodium complex
for 24 h (except [Rh(DIP)2(chrysi)]3+, which was administered at 2 μM).
Komor et al. Page 18
J Am Chem Soc. Author manuscript; available in PMC 2013 November 21.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 4.
Differential cytotoxicities of rhodium metalloinsertors. HCT116N (green) and HCT116O
(red) cells were plated in 96-well format at densities of 5 × 104 cells/well and treated with
the concentrations of rhodium metalloinsertors indicated. After 72 hours, the cells were
labeled with MTT for 4 hours.
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Figure 5.
ICP-MS assay for whole-cell rhodium accumulation. HCT116O cells were treated with 10
μM of each rhodium complex (except [Rh(DIP)2(chrysi)]3+, which was administered at 2
μM) for 1, 3, 6, 12, or 24 h. The cells were analyzed for rhodium content by ICP-MS. The
rhodium counts were normalized to protein content, which was determined by a BCA assay.
See Experimental.
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Figure 6.
ICP-MS assay for nuclear and mitochondrial rhodium accumulation. HCT116O cells were
treated with 10 μM of each rhodium complex (except [Rh(DIP)2(chrysi)]3+, which was
administered at 2 μM) for 24 h. The cells were harvested by trypsinization and appropriate
organelle isolation procedures performed. The mitochondrial rhodium counts were
normalized to protein content, which was determined by a BCA assay. The nuclear rhodium
numbers were normalized to number of nuclei.
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Table 1
Qualitative nucleara and mitochondrialb uptake properties, as well as the presence or absence of cell-selective
biological activityc for all ten metalloinsertors.
Compound Nuclear Conc.a Mito. Conc.b Cell- Selective Activityc
[Rh(NH3)4(phzi)]3+ + − +
[Rh(chrysi)(phen)(DPE)]3+ + − +
[Rh(DPAE)2(chrysi)]3+ + − +
[Rh(HDPA)2(chrysi)]3+ + + +
[Rh(chrysi)(phen)(HDPA)]3+ + + +
[Rh(bpy)2(chrysi)]3+ + + −
[Rh(chrysi)(phen)(MeDPA)]3+ + + −
[Rh(chrysi)(phen)(PrDPA)]3+ + + −
[Rh(PrDPA)2(chrysi)]3+ + + −
[Rh(DIP)2(chrysi)]3+ + + −
aCompound is considered to have “+” nuclear concentration if its nuclear concentration is sufficient for mismatch detection given its binding
affinity.
bCompound is considered to have “+” mitochondrial concentration if its mitochondrial rhodium concentration is ≥200 ng Rh/mg [mito protein].
cCompound is considered to have “+” cell-selective activity if its differential inhibition of DNA synthesis as measured by ELISA of the MMR
proficient line versus the MMR deficient line is ≥25% at 24 hr of incubation, 10 μM compound concentration.
J Am Chem Soc. Author manuscript; available in PMC 2013 November 21.
